

Glenmark Pharmaceuticals B.V.

at Amsterdam

Financial report 2022/2023



Index

Financial statements	3
Balance sheet as at March 31, 2023	4
Profit and loss account for 2022/2023	6
General notes	7
Accounting policies	8
Notes to balance sheet	10
Notes to profit and loss account	14
Other notes	16

FINANCIAL STATEMENTS

Balance sheet as at March 31, 2023

Assets

<i>(after profit appropriation)</i>	€	31 March 2022	€	31 March 2022	€
<i>Non-current assets</i>					
Intangible assets		12,214		24,428	
Equipment		11,340		14,462	
<i>Current assets</i>					
Inventories		3,441,586		2,328,884	
<i>Receivables</i>					
Trade receivables	4,402,512		3,985,940		
Group companies	35,009		29,641		
Tax receivables	60,136		-		
Other receivables	60,735		38,303		
		4,558,392		4,053,884	
Cash and cash equivalents		5,809,740		3,931,371	
Total		13,833,272		10,353,029	

Equity and liabilities

(after profit appropriation)

	31 March 2022		31 March 2022	
	€	€	€	€
<i>Equity</i>				
Share capital	18,000		18,000	
Other reserves	2,231,598		1,896,894	
		2,249,598		1,914,894
Non-current liabilities		-		10,650
<i>Current liabilities</i>				
Trade payables	1,017,912		378,789	
Group companies	695,083		1,628,576	
Taxes payable and social security contributions payable	285,426		321,975	
Other payables	-		12,209	
Accruals	9,585,253		6,085,936	
		11,583,674		8,427,485
Total		13,833,272		10,353,029

Profit and loss account for 2022/2023

	2022/2023		2021/2022	
	€	€	€	€
Net revenue	13,152,115		12,794,394	
Other operating income	141,407		1,732	
Cost of sales	-11,442,375		-10,999,266	
Gross margin		1,851,147		1,796,860
Employee benefits	707,131		504,101	
Amortisation, depreciation and impairment	17,113		16,380	
<i>Other operating expenses</i>				
Other operating expenses	718,388		456,360	
Sum of expenses		1,442,632		976,841
Operating result		408,515		820,019
Financial income and expense		-5,134		-1,406
Result before tax		403,381		818,613
Income tax expense		-68,677		-180,423
Result after tax		334,704		638,190

General notes

Most important activities

The activities of Glenmark Pharmaceuticals B.V., having its legal seat at Amsterdam primarily consist of: the purchase and sales of medicine.

Location actual activities

The registered and actual address of Glenmark Pharmaceuticals B.V. is Gooimeer 1 , 1411 DC te Naarden in Registered place of business and is registered at the chamber of commerce under number 50131893.

Accounting policies

General

General policies

The financial statements are drawn up in accordance with the provisions of Title 9, Book 2 of the Dutch Civil Code and the firm pronouncements in the Dutch Accounting Standards, as published by the Dutch Accounting Standards Board ('Raad voor de Jaarverslaggeving').

Accounting policies for the valuation of assets and equity and liabilities

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise, the relevant principle for the specific balance sheet item, assets and liabilities are presented at face value.

Accounting policies for the income statement

Income and expenses are accounted for on accrual basis. Profit is only included when realized on balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

Changes in accounting estimates

The commission on sales expenses have been deducted from the revenue. Due to the new classification, the comparable figures have also been adjusted.

Accounting policies for assets

Intangible assets

Intangible fixed assets are presented at cost less accumulated amortisation and, if applicable, less impairments in value.

Equipment

Tangible fixed assets are presented at cost less accumulated depreciation and, if applicable, less impairments in value.

Inventories

Inventories (stocks) are valued at historical price or production cost based on the FIFO method (first in, first out) or lower realisable value.

Receivables

Upon initial recognition the receivables are recorded at the fair value and subsequently valued at the amortized cost. The fair value and amortized cost equal the face value.

Cash and cash equivalents

Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is carried at nominal value.

Accounting policies for equity and liabilities

Non-current liabilities

Recorded interest-bearing loans and liabilities are valued at amortized cost.

Accounting policies for the income statement

Net revenue

Revenues from the goods supplied are recognised when all significant risks and rewards in respect of the goods have been transferred to the buyer.

Income tax expense

The corporation tax is calculated at the current rate on the result of the financial year, taking into account permanent differences between the profit calculation according to the annual accounts and the tax profit calculation, and where deferred tax assets (if applicable) are only valued insofar as the realization thereof probably is.

Notes to balance sheet

Intangible assets

	<u>31 March 2022</u>	<u>31 March 2022</u>
	€	€
Right of use assets	12,214	24,428
Total	<u>12,214</u>	<u>24,428</u>

The overview below shows the movements in the intangible fixed assets during the financial year:

	<u>Right of use assets</u>
	€
<i>Carrying value April 1, 2022</i>	
Cost or manufacturing price	36,643
Accumulated amortisation and impairments	<u>-12,215</u>
	24,428
 <i>Movements 2022/2023</i>	
Depreciation	<u>-12,214</u>
	-12,214
 <i>Carrying value March 31, 2023</i>	
Cost or manufacturing price	36,643
Accumulated depreciation	<u>-24,429</u>
	<u>12,214</u>

Equipment

	<u>31 March 2022</u>	<u>31 March 2022</u>
	€	€
Other tangible assets	11,340	14,462
Total	<u>11,340</u>	<u>14,462</u>

The overview below shows the movements in the tangible fixed assets during the financial year:

	Other tangible assets
	€
<i>Carrying value April 1, 2022</i>	
Cost or manufacturing price	23,703
Accumulated amortisation and impairments	-9,241
	<u>14,462</u>
<i>Movements 2022/2023</i>	
Additions	1,777
Depreciation	-4,899
	<u>-3,122</u>
<i>Carrying value March 31, 2023</i>	
Cost or manufacturing price	25,481
Accumulated amortisation and impairments	-14,141
	<u>11,340</u>
Depreciation rate (average)	20.0

Inventories

	31 March 2022	31 March 2022
	€	€
Inventory of finished and trade goods	3,441,586	2,328,884
Total	<u>3,441,586</u>	<u>2,328,884</u>

Receivables

	31 March 2022	31 March 2022
	€	€
Trade receivables, gross	4,402,512	3,985,940
Group companies	35,009	29,641
<i>Tax receivables</i>		
Corporate income tax	60,136	-
Other receivables	60,735	38,303
Total	<u>4,558,392</u>	<u>4,053,884</u>

Cash and cash equivalents

	31 March 2022	31 March 2022
	€	€
Bank credits	5,809,740	3,931,371
Total	<u>5,809,740</u>	<u>3,931,371</u>

Equity

	31 March 2022	31 March 2022
	€	€
Share capital	18,000	18,000
Other reserves	2,231,598	1,896,894
Total	<u>2,249,598</u>	<u>1,914,894</u>

The overview below shows the movements in the equity during the financial year:

	Share capital	Other reserves	Total
	€	€	€
Balance April 1, 2022	18,000	1,896,894	1,914,894
<i>Movements 2022/2023</i>			
Result for the year	-	334,704	334,704
	<u>-</u>	<u>334,704</u>	<u>334,704</u>
Balance March 31, 2023	<u>18,000</u>	<u>2,231,598</u>	<u>2,249,598</u>

Share capital

The issued share capital of the company amounts to € 18.000, divided into € 18.000 ordinary shares. The total number of issued shares is 18.000.

Non-current liabilities

	31 March 2022	31 March 2022
	€	€
Other payables	-	10,650
Total	<u>-</u>	<u>10,650</u>

Disclosure

Repayment obligations falling due within 12 months from the end of the financial year, as set out above, are included in current liabilities.

Current liabilities

	31 March 2022	31 March 2022
	€	€
Trade payables	1,017,912	378,789
Group companies	695,083	1,628,576
<i>Taxes payable and social security contributions payable</i>		
Corporation income tax	-	119,719
VAT	285,426	202,256
	<u>285,426</u>	<u>321,975</u>
Other payables	-	12,209
Accruals	9,585,253	6,085,936
Total	<u>11,583,674</u>	<u>8,427,485</u>

Notes to profit and loss account

Revenue and gross margin

	2022/2023	2021/2022
	€	€
Net revenue	13,152,115	12,794,394
Other operating income	141,407	1,732
Operating income	13,293,522	12,796,126
Cost of sales		
Purchase of traded goods	12,555,077	10,976,468
Change in inventory	-1,112,702	22,798
	11,442,375	10,999,266
Gross margin	1,851,147	1,796,860

Employee benefits

	2022/2023	2021/2022
	€	€
Wages and salaries	606,551	442,406
Social security contributions	7,432	2,628
Pension costs	93,148	59,067
Total	707,131	504,101

Amortisation, depreciation and impairment

	2022/2023	2021/2022
	€	€
Depreciation of right-to-use assets	12,214	12,215
Depreciation of tangible assets	4,899	4,165
Total	17,113	16,380

Other operating expenses

	2022/2023	2021/2022
	€	€
Other operating expenses		
Advice	89,073	107,829
Transport expenses	170,287	187,939
Insurance expenses	30,765	28,660
Sales expenses	42,514	49,883
Subscriptions	69,005	30,036
Recruitment expenses	-	27,657
Office expenses	12,858	4,924
Audit, accounting and payrolling fees	5,900	5,900
Bank charges	371	2,053
Penalty	280,000	-
Other expenses	17,615	11,479
Total	<u>718,388</u>	<u>456,360</u>

Financial income and expense

	2022/2023	2021/2022
	€	€
Interest expenses other parties	-5,134	-1,406
Financial income and expense	<u>-5,134</u>	<u>-1,406</u>

Taxation

	2022/2023	2021/2022
	€	€
Income tax expense from ordinary activities	<u>68,677</u>	<u>180,423</u>

Other notes

Profit appropriation

Appropriation of the results

The annual report will be adopted in the general meeting of shareholders.

Proposed appropriation of the results

It is proposed that the appropriation of result by the board of directors and pursuant to the articles of association, an amount of € 334,704 will be add to the other reserves.

Signature

Amsterdam,

Name

Function

Signature

O. Bourne

Managing director

INDEPENDENT AUDITOR'S REPORT

To: Directors and shareholders of Glenmark Pharmaceuticals B.V.
Gooimeer 1
1411 DC Naarden

We have audited the accompanying financial statements for the year ended March 31 2023 of Glenmark Pharmaceuticals B.V., Amsterdam, which comprise the balance sheet as at 31 March 2023, the profit and loss account for the year then ended and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Glenmark Pharmaceuticals B.V. as at March 31, 2023 and of its result for the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Haarlem, 28 April 2023



A.M. Lansbergen RA
Clic Accountants B.V.